Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alnylam Ends Revusiran In Phase III, But Was Failure Due To Safety Or Efficacy?

Executive Summary

Alnylam’s stock fell more than 40% in after-hours trading following the decision to end development of revusiran based on an imbalance of deaths in the Phase III ENDEAVOR clinical trial, but executives see no read-through to the rest of the company’s RNAi platform.

Advertisement

Related Content

Stockwatch: Alnylam Helps Nucleic Acid Drugs Degrade
Alnylam's 'Day After' Revusiran Failure Bad, Maybe Not Catastrophic
Alnylam's Fitusiran Could Provide Comprehensive Hemophilia Therapy Option
Ionis Antisense Platform Safety Questioned After Thrombocytopenia Seen In Studies

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097429

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel